

美中生物医药协会会刊

# CABA *Connect*

Chinese-American BioMedical Association Official Newsletter

SUMMER 2010  
VOLUME 2, ISSUE 1



🌀 *in this issue* 🌀

- ✧ President's Message (P.2)
- ✧ 2010 CABA Annual Conference Reports (P.4)
- ✧ NESACS-CABA Joint Conference (P.8)

*Published by Chinese-American BioMedical Association*

CABA  
P. O. Box 600241  
Newtonville, MA 02460

# A Message from the President



CABA Connect

Dear CABA members and friends,

With great pleasure we present you this *CABA Connect*. Thanks to Drs. Qinglin Che, William Wang, Tony Yuan and the rest of the editorial team for their dedication and hard work in bringing us another wonderful newsletter! *CABA Connect* documents CABA's major events and organizational matters in a timely fashion. It helps connect us effectively and reach out more to serve this volunteer-based community!

Planted in Boston, the world's capital of intellectuals and hub of biomedical innovations, CABA has grown into a full-fledged organization in only three years. Browsing through this issue of *CABA Connect*, you will notice that we firmly adhere to our missions: (i) to serve as a platform for our members to network and to help their career development; (ii) to serve as a bridge to connect our members with the scientific and business resources in China thus facilitating collaborations between US and China in the bio/pharmaceutical fields. Meanwhile, you will find that our events and activities are going in more depth and reaching out to broader professional and geographical areas.

For 2010, we put special emphasis on three core symposia: CABA's annual conference in April; Technology, Investment and Entrepreneurship Symposium in November; and Medical Device and Diagnostics Symposium in December. For each one, dedicated teams are set up ahead of time, high caliber speakers are actively sought after, and agendas are thoroughly planned. On top of these three symposia, we set up special training programs and expert forums that provide members unique educational opportunities on topics of their interest. This year's pharmaceutical/medical device regulatory training class is attracting a growing number of attendees and covering a wider range of topics. In May, we co-hosted a special symposium on "Drug R&D in China" with Northeastern Section of American Chemical Society (NESACS) to specifically discuss innovative new drug R&D activities in China, a sector recently in rapid growth but lacking more in-depth coverage previously compared to the maturer CRO industries in China.

With a broader network, we collaborate cohesively with many other professional, business and student organizations locally, nationally and internationally. Riding the success of last year's summer outing of 4 organizations, CABA collaborated with 11 professional organizations and co-organized the 2010 New England Chinese New Year Gala, which was unprecedented in both scale and influence in the history of local community activities. Summer outing and New Year gala are now becoming our two annual social events for members along with their families to network each other and with other professionals in the greater Boston area. Nationally, we helped build up the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA), which is comprised of CABA in Washington DC, CABS in San Francisco, SABPA in San Diego, and CABA in Boston. Each operating independently, these 4 sister organizations actively share resources and join forces to achieve greater success beyond the four key geographic locations in US. Across the continent, we collaborate with many bio & industrial parks and agencies in China. So far in 2010, CABA has coordinated Boston visits of delegations from Beijing, Wuhan, Wuxi, Tianjin, Sutong, Changzhou etc. to recruit talents and to explore business opportunities.

As an organization built by members to serve members, we are extremely grateful that many more members are stepping up to help serve our CABA community. We now have 32 executive committee members and over 35 coordinators in addition to a dedicated legal council and 19 distinguished advisors, and we always welcome volunteers! With your active participation and support, together we can definitely build an even stronger CABA community!

Sincerely yours,

Chaoyang Dai  
President 2010-2011  
Chinese-American BioMedical Association (CABA)

*Editor-in-Chief:*  
Qinglin Che

*Volume Chief Editor:*  
Yongzhong Wang

*Contributing Editors:*  
Tony Yuan, Zhihong Chen,  
Zhiyong Yang, Jingye Zhou  
Hanlan Liu, Fred Hu

*Board of Publications:*  
Chaoyang Dai, Jun Han,  
Yihan Wang, Zhao-Kui Wan,  
Junjun Wu, Zhiyong Yang,  
Phil Zhang

*Photographers:*  
Jun Han, Zhonghe Li, Qinglin  
Che, Fred Hu, Chutze Chou

CABA CONNECT  
Volume 2, Issue 1

Published by:  
CABA  
P. O. Box 600241  
Newtonville, MA 02460 USA  
[www.cabaweb.org](http://www.cabaweb.org)

If you want to subscribe to this  
newsletter, please send your  
request with updated mailing  
address and member  
information to  
[cabaconnect@gmail.com](mailto:cabaconnect@gmail.com)

## In This ISSUE

---

2. **Message from the President**
4. *CABA Event Report*  
**2010 CABA Annual Conference Report: From traditional Chinese herbal extract soup to chemically designed and synthesized molecular medicine: Innovation means “East Meets West”**
8. *NESACS-CABA Joint Conference*  
**Drug R & D in China: Status, Opportunity, International Collaboration & Challenges**
10. *“Connecting China” Special Event*  
**Beijing-Boston BioMedical Promotion Forum**
11. *Celebrating Chinese New Year!*  
**新英格兰12华人专业团体社区论坛及春节联欢晚会**
- 14-17. *“Connecting China” Special Events*  
**湖北省海外高层次人才招募恳谈会; 中国苏通科技产业园代表团访波士顿进行推介活动; “药物研发在中国” 学术研讨会; 第十届华创会**
18. *BioMedical News Round-up*
19. *Selected Industry Jobs (Boston and China)*
21. *CABA Leadership Team Update*  
**CABA 2010 Executive Committee, Board of Directors and Advisors**
22. *Sponsorship Update*

**Disclaimer:** *CABA Connect* reserves the right to edit, publish, or reject any submission or its contents. Any articles published by *CABA connect* may not be published elsewhere without CABA's consent and permission. Each article represents the author's opinion, not necessarily that of CABA.

## Report on CABA 2010 Annual Conference

# From traditional Chinese herbal extract soup to chemically designed and synthesized molecular medicine: Innovation means “East Meets West”

Reported By William Yongzhong Wang, Ph.D.

To many people in Boston, it might sound mildly insane to forgo a gorgeous spring Saturday in the wake of a long winter pounded by heavy snows and two consecutive once-a-century rains that left unpleasant water marks in way too many basements. But for over 300 biomedical professionals including senior executives, established scientists and seasoned managers from major pharmaceutical companies and prominent thought leaders from academic institutions, it was apparently still ok to miss the long-awaited warm sunshine and cozy breeze, even if it meant to wake up early and show up at 8am on Saturday, April 10 inside the MIT faculty club.

The prize, as it turned out, was the Chinese American Biomedical Association (CABA) 2010 annual conference. The theme of the conference was “Biomedical Today-East meets West”. In his opening keynote speech, Professor Ken Kaitin, an internationally recognized expert in the science of drug development and the Director of the Center for Study of Drug Development at Tufts University, effectively ‘woke up’ the audience by pointing out that the old model of drug development that drives the industry by focusing on a few blockbuster drugs has become unsustainable due to rising cost and diminishing output. A fully integrated pharmaceutical network (FIPNET) model that combines the strength of academic innovation and industrial development needs to be in full play in order to move more drugs through development pipelines more quickly and cost-effectively. As the developing market, especially the so-called BRIC countries (Brazil, Russia,

India and China), will account for a more significant growth, Dr. Kaitin called for more active collaborations with a global perspective.

Dr. Kaitin’s view was shared by nearly every following speaker from top Chinese contract research organizations (CROs), which have become a dominant global force in drug discovery and development. Dr. Jim Zhang, CEO of JZ Med Inc., gave the first session of the conference, “China perspectives: Innovative Drug R&D and Contract Research,” a jump-start by methodically mapping out the overall innovative drug R&D in China. In sharp contrast to the struggling capital situation in the US, he told the audience, “With financial backing from both the Chinese government and private investors, money is basically not an issue for drug R&D in China nowadays!” Dr. Brian Manning, Director of Genscript, also cited government support in addition to low cost and growing domestic market as one of China’s major advantages. Dr. Derek Ron, VP of Viva Biotech Ltd., used his own company to demonstrate that, as most Chinese CROs push for integrated services, there are still significant opportunities for niche markets. With a focus on fragment based drug design & development, his company grew from a few scientists to nearly 200 scientists in a couple of years. Dr. Joanne Jiang, VP of Fountain Medical Development Ltd., offered another example by highlighting Fountain’s specific focus on clinical services and its remarkable growth in recent years.

The second session of the conference focused on the trends and new development in Integrated R&D Services. After reviewing the historical role of Chinese CROs, Dr. Charles Huang, VP of Sundia MediTech, mentioned that they have so far paid little attention to the development of their



Over 300 hundred attended CABA annual conference on April 10, 2010 in Cambridge, MA

own intellectual properties (IPs) despite their dramatic growth and significant contributions to global drug R&D. However, as a “side effect”, they have been training numerous professionals and many emerging biotech companies in China would eventually benefit from it. In addition, Dr. Huang reminded CABA that it should also thrive to play a historical role in the process thanks to its ideal location in Boston, one of the world’s largest centers in biopharmaceutical industry and academic research, and its unique member base of numerous China-born and west-trained talents. “That’s east meets west”, Dr. Huang declared. With increasing competitions, Chinese CROs are moving towards a more integrated model, in some cases with a risk-sharing perspective, as pointed out by Dr. Yajun Xu, SVP of ShangPharma & ChemPartner, Dr. TJ Deng, VP of BioDuro, and Dr. Jinbo Lee, Senior Advisor for Shanghai Medicilon. Dr. Yujun Xu encouraged the audience to explore China. “There are plenty of opportunities”, she mentioned.

For overseas professionals with a keen entrepreneurship spirit, the third session of the conference provided a highly anticipated opportunity to closely interact with China’s biomedical parks and enterprises. Mr. Ping Tse, CEO of Sino Biopharmaceutical Ltd., Executive Director of the international giant Chia Tai Enterprises International LTD and one of the most successful foreign investors in China’s pharmaceutical sector, led a delegation of 8 senior executives and directors to the CABA annual conference. His presence and a brief introduction of his business reach effectively wowed everyone in the audience. There was also plenty of laughter in the audience when he shared a few inside stories about his business adventures in China that started almost immediately after the country opened its doors thirty years ago. He told the audience that his enterprise is actively exploring new business opportunities and invited those who had creative ideas but needed financial support to have one-on-one meetings with him in the hotel he stayed the next day. Having a simple box lunch after the session ended, a rare occasion for one of Asia’s richest people living in one of world’s best places for fine cuisine-Mr. Tse mostly lives in Hong Kong, Mr. Tse was as enthusiastic as everyone who talked to him about potential collaboration opportunities.

China CRO’s new development and improved models will undoubtedly benefit the biopharmaceutical industry by increasing productivity, lowering cost and shortening concept-to-market time. However, as Dr. TJ Deng of BioDuro pointed out, scientific innovations are still the key for the growth of the industry. Innovation was indeed the focus of the fourth session of the conference, titled “Leading the way: innovation as driving force to energize biomedical industry.” The session featured Dr. Duanqing Pei, President of Guangzhou Institute of Biomedicine and Health, Dr Youssef Bennani, VP of Vertex Pharmaceuticals, Dr. William Shakespeare, VP of Ariad Pharmaceuticals and Dr. Matt Clark, Director of GSK’s Molecular Discovery Research in Boston. Previously a professor at University of Minnesota, Dr. Duanqing Pei returned to China in 2004 and has built one of China’s top research teams in stem cell research. His team recently made worldwide news by discovering that vitamin C can improve the conversion efficiency of adult cells to induced pluripotent stem (iPS) cells by 100 folds. In another innovative move, he created a new “Chief Technology Officer” position in his institute



Some attendees signed up for CABA membership during registration.

and recruited Dr. Micky D. Tortorella, most recently a senior principal scientist from Pfizer, to speed up the translation of research discoveries to real therapeutics-yet another example of “east meets west”. Dr. Youssef Bennan of Vertex enlightened the audience how to learn from the nature and develop natural product-inspired drugs, which accounts for over 50% prescription drugs and targets over 80% of known diseases. Dr. William Shakespeare of Ariad did not let the chemists in the audience wait too long before he gave them a healthy dose of medicinal chemistry as well as some insights into the discovery of AP24534, a novel multi-targeted kinase inhibitor. Dr. Matt Clatt told the audience that some parts of drug discovery nowadays are shifting from knowledge-based model to a screening-based model. For small organizations without big resources, his company’s technology based on DNA-encoded small molecule library can lower the initial hurdle of drug discovery. As an example, he termed one of such techniques “ligand discovery at your fingertips.”

The fifth session of the conference switched the attention from scientific innovations to the “big picture”, as indicated in the title “Broaden the horizon: biomedical R&D partnership in Asia-pacific/China.” Dr. Tom Evans, VP of Novartis China, reiterated the advantages of doing translational research in China including high patient compliance, ease of impatient care, fast enrollment, huge capacity, very good quality control and unmatched talent pool. “For example,” he mentioned, “all the CROs Novartis works with passed FDA audit without any problem.” Novartis has indeed invested ~1 billion USD in China. However, he quickly brought the



Dr. Chaoyang Dai, CABA president (2010-2011) co-hosted the opening keynote section and the dinner reception.

audience back to some tough realities. “China’s good clinical practice (GCP) and international GCP are not the same,” he pointed out. Overall, there are still many hurdles remaining such as lack of knowledge, a weak and overworked regulatory agency, lack of effective enforcement of law, lack of transparency in the clinical application

review system, etc. “The food is better than the US, but the movies are bad,” he finally added. When I later asked him what recent American movie qualifies a good rating according to his standard, he quickly answered “Avatar, but the ticket line was five hours in China.”

Compared to the huge investment of Novartis in China, Genzyme’s planned \$100 million investment seems small. “But our CEO is a frugal Dutch, I am pretty sure the \$100 million will go a long way,” Dr. Jim Burns, SVP of Genzyme, humorously reminded the audience in his speech following Dr. Evans. In fact, Genzyme placed China as one of the most important strategic places for its future growth and is setting up a big facility in Beijing. In addition, it has used its humanitarian assistance for neglected diseases (HAND) program to give back to society for many years. Beginning last year, Genzyme has donated nearly RMB 200 million (~\$30 million) annually for the treatment and drug costs for 134 sufferers of gaucher disease, a genetic disorder, in China. In addition, Genzyme donates RMB 2 million (\$292,825) to the Rare Disease Relief Public Fund for training doctors and raising public awareness about rare diseases.



Seasoned pharmaceutical experts from Novartis, Pfizer, Merck, Sinobiopharma etc compose the panel.

Dr. Evans and Dr. Burns were later joined by Dr. Reid Leonard, executive director of Merck, Dr. Gangfeng Xu, most recently ACP of Pfizer, and Mr. Ping Tse for a panel forum. The audience quickly found the questions raised were sharp and answers from the senior executive panel on point, as well as time was unfortunately not on their side because the forum had to wrap up at 5:30pm according to schedule. However, the following cocktail social hour provided the perfect opportunities for the discussions to continue. Like last year, the conference was sponsored by major biopharmaceutical companies and attracted many vendors to showcase their products. Many companies also posted their job openings, which quickly became the focuses of numerous active conversations.

Over 90 attendees stayed for the dinner reception, which featured two keynote speeches delivered by Dr. Whaijen Soo, SVP of Shire and Dr. Suvit Thaisrivongs, VP of Pfizer. Dr. Soo gave a detailed analysis of the underlying rationales of many pharmaceutical companies’ China strategy. As China’s health care coverage continues to expand dramatically, China’s drug market will continue to grow rapidly, especially in some unique disease areas such as hepatitis. It is therefore not a surprise to see some global pharmaceuticals such as GSK to launch drugs for China and China only. He also proposed a new “value-chain model” for drug development and organic expansion of many companies in China. Dr. Thaisrivongs opened his speech with his own experience as a Thai Chinese growing up in Bangkok and taking traditional herbal medicines when he got sick. “I always tried to show my parents that the brownish herbal extract soup worked because I did not want to take it again the next day,” he joked. In nearly 30 years after getting a Ph.D. in synthetic organic chemistry, he has invented and delivered a number of drug candidates for clinical trials and eventually registered medicines including Aptivus, a protease inhibitor drug for adult HIV patients. (Of course, readers with a keen sense of spelling might have found that Dr. Suvit Thaisrivongs’s first name, in backward order, is part of the commercial name of the drug. He later mentioned that PA stands for Paul Aristoff, who was one of the other lead chemists on this project.) On his philosophy in drug development, he told the audience that scientists need to always remember “patients first” and take a “begin with end in mind” approach.



On winning strategy, he said one needs to “know yourself” and “know your competitors.” “Plan ahead and analyze your strength and weakness, understand yours and your competitor’s next move”, he told the audience, “like playing chess, you always need to see four moves in advance and take calculated risks to win the game.” To many ambitious scientists in the audience, his philosophy and the leap of faith he experienced from having to take the brownish herbal extract soup to chemically designing and synthesizing medicine targeting a specific disease was a perfect dose of advice.

commented after the conference, “... an outstanding conference on Saturday. I really enjoyed the speakers and the high level of energy and excitement in the room.”

So, for those like Bill who chose to stay inside to attend the CABA conference on that gorgeous spring Saturday, it wasn’t a bad deal after all.

In the end, as Dr. Thaisrivongs said, all we do is “making medicine that matters.” And all CABA thrived to do via the annual conference and other activities is to help connect the east with the west and make that happen. As Bill Madden, Associate Director of business development at Vertex



## ***NESACS-CABA Joint Conference Focused on Drug R&D in China***

# **Drug R & D in China: Status, Opportunity, International Collaboration & Challenges**

*Reported by Fred Hu, Ph.D.*

More than 150 scientists and professionals from both academic and biotech industry gathered in Holiday Inn of Woburn, MA on May 22, 2010 for a scientific symposium featuring "Drug R&D in China: Status, Opportunity, International Collaboration and Challenges". The symposium was co-organized by Northeastern Section of American Chemical Society (NESACS) and Chinese -American BioMedical Association (CABA).

Chair of NESACS Dr. Liming Shao and President of CABA Dr. Chaoyang Dai presided the meeting sessions. Both Drs. Shao and Dai pointed out that with strong government support and the return of talented overseas scientists, China's innovative drug R&D has just gathered its momentum in recent several years.

The meeting was divided into three main themes: Drug discovery in China and Chinese pharmaceutical industry – status and trends; Leverage China's drug discovery through international collaboration; and Challenges and opportunities of drug R&D in China.

At the meeting, prominent academic professors and seasoned industrial scientists and executives from both China and US shared their views on China's drug R&D and the impact on the global pharmaceutical industry. Invited speakers included Professor Jingkang Shen of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Dr. Christopher-Paul Milne, associate director at Center for the Study of Drug Development, Tuft University; Professor Hongbin Sun of China Pharmaceutical University; Dr. Michael Song, CSO of KBP Biosciences; Dr. Bruce Littlefield of Harvard Medical School; Dr. Hongjun Yang, president of Suzhou Sirnaomics Biopharmaceuticals; Dr. Zhijian Lu, Director of Pfizer Asia Global Biotherapeutics Technologies, and Dr. Luciene Ronco of AstraZeneca Discovery Medicine and transitional Science.

As an expert in drug R&D, Professor

Jingkang Shen gave an insider view of the past, present and future drug discovery in China. "The Chinese government encourages drug R&D innovation", he stated. After its implementation in 1985, the Chinese patent law has been amended three times since 2008. The pharmaceutical and drug registration law has also been amended in 2007. All these amendments help innovation in

drug research and development. He also explained in detail why China has a huge potential for drug discovery industry. With a large and aging population and recently developed medical insurance system, China has an ever increasing demand for new medicines. The rapid GDP growth in China also provides necessary funding for drug R&D in China.

Prof. Jingkang Shen also gave an introduction about a few successful pharmaceutical companies and drug research institutes in China. Shanghai pharmaceutical group, for example, is now the second largest pharmaceutical company in China. The company has 2900 products with revenue of 34.8 billion yuan. It also registered a total of 277 new drugs and 248 patents.

Dr. Christopher-Paul Milne, gave a global view of Chinese pharmaceutical industry. Chris has visited China many times,





including a recently visit to study Chinese drug market. “Numbers tell a story”, he said. The large population, rapid GDP

growth and huge wealth in China have drawn much attention from global pharmaceutical industries. “Changes float”, he told the audience. The pharmaceutical industry has shifted its resources out of the developed countries to reduce cost. “Opportunities fly”, he stressed. Don’t miss out the golden opportunity to do drug R&D in China.

Prof. Sun Hongbin quoted John Lechleiter, CEO of Eli Lilly, that the pharmaceutical industry has spent too much time, money, and produced few products. He felt that there is a very urgent need to revive the pharmaceutical industry. He discussed a few strategies for innovations in drug research. One strategy is to re-discover the old drugs to find their new uses. For example, Eli Lilly’s Raloxifene used for treatment of osteoporosis, can now be used for treatment of breast cancer. Celgene’s Thalidomide was originally developed for erythema nodosum. It can now be used for multiple myeloma. A second strategy is, as Prof. Hongbin Sun pointed out, the combination of drugs for medical treatment. This method has been widely used in recent years, including anti-AIDS and anti-cancer drug cocktail. He also presented some of his current research efforts on pro-drugs, metabolite synthesis, and chiral switch in drug discovery.

Dr. Bruce Littlefield shared with us his international collaboration experience to identify new therapeutic opportunities for TCM (Traditional Chinese Medicine). His research program has built a library of authenticated, quality



controlled, source-documented TCM plants at Harvard Medical School. The TCM library is a collection

of valuable samples from 205 fields in China. The program is currently looking for new funding opportunities.

Dr. Honghun Yang impressed audience with RNAi therapeutics in China. Sirnaomics has three generations of nanoparticle-mediated SiRNA delivery systems. The company uses SiRNA cocktail design to successfully target pandemic influenza and angiogenesis. A few SiRNA cocktails, including STP601, STP 702 and STP705, have either demonstrated animal efficacy or completed pre-IND.

Scientists from pharmaceutical giants Pfizer and discussed their R&D approach and strategies in the emerging markets. Dr. Zhijian Lu talked about Pfizer’s China R&D center, network of partner in Asia and its joint forces with Lilly and Merck to accelerate research to improve treatment of lung and GI cancer. Dr. Luciene Ronco from AstraZeneca talked about AZN’s investment in China and ICC’s (Innovation Center China) contribution to biomarker strategy and clinical implementation of EGFR mutation testing.

Other speakers include Dr. Philip Zhang of Principal Milstein Zhang & Wu LLC. And Mr. Michael McGurk from Partner (Finnegan) who touched upon IP protection in China; Dr. Sam Liao from Novartis and Dr. Peng Wang from Sincere Pharmaceutical Group who talked about current status and future opportunities in China.



**“Connecting China” Special Event****Beijing-Boston BioMedical Promotion Forum**

Reported by Fred Hu, Ph.D.

Beijing/Boston biomedical promotion forum was held on July 3, 2010 at Massachusetts Institute of Technology faculty club in Cambridge, MA. More than 80 scientists and professionals from both academic and biotech industry attended the forum. The event was organized by Chinese-American BioMedical Association (CABA).

Beijing Biotech delegation, a team of 11 people, was led by Mr. Weimin Zhou, deputy director of Beijing Investment Promotional Bureau and Mr. Hesheng Wang, deputy director of Beijing Economic and Technological Development Zone. Dr. Chaoyang Dai, president of CABA, presided over the forum.

Mr. Weimin Zhou and Mr. Hesheng Wang gave an introductory overview over Beijing’s biomedical industry and Beijing Economic and Technological Development Zone. They mentioned, as China’s capital, Beijing is the political, cultural, international and domestic exchange center. It gathers a large number of national research institutes and universities full of talented people and is the best city in China in terms of intellectual property protection. Biomedical industry is one of Beijing’s pillar industries. The State Food and Drug Administration and nearly 50 state-level hospitals with clinical



From left: Dr. Zhao-Kui Wan, Prof. Yuwei Li, Mr. Weimin Zhou and Dr. Chaoyang Dai at the forum.

research capabilities are located in Beijing, providing a unique environment for Beijing’s bio-pharmaceutical industries. Beijing

Economic and Technological Development Zone brings together National Human Genome Research Center, State 863 Biological Research Base on Viral Gene Vector, National New Vaccine Engineering Research Center and a large number of excellent biomedical enterprises. It has become an ideal fertile ground for biomedical industry.

The introduction on Beijing Biomedical industry and Beijing Economic and Technological Zone was followed by exemplary successful stories by entrepreneurs such as Dr. Zhiliang Li, CEO of AutekBio, Inc.; Dr. Xu Huan, General manager of Sino Biological, Inc.; and Dr. Eric Zhang, President and CEO of Beijing PharmaSciences.

In order to further promote the biomedical industry in Beijing Economic and Technological Development Zone, 1 to 1 meetings between Beijing delegates and individuals from Boston Biotech Industry were held in Hyatt Hotel on July 2, 2010.



CABA organizers of the forum with guests from Beijing.

**特别报道 (special report)****记新英格兰12华人专业团体社区论坛及春节联欢晚会*****New England Chinese Professionals' Chinese New Year Gala***

侨报周刊记者 魏莎 波士顿报道

2月14日喜逢大年初一，新英格兰地区12家华人专业协会举办了有近600人参加的2010华人专业人士社区论坛、新春晚宴和联欢晚会。此次盛大的喜庆新春、回报社区的活动地点在波士顿近郊牛顿市的Marriott酒店。本期“波城故事”，记者为您记录下活动当天的精彩场面。

这次对北美专业华人社团有著历史性意义的活动由北美中华医学学会(ACMA)，美中生物医药协会(CABA)，中美知识产权法律协会(CAIPLA)，全美华人金融协会(TCFA)，128华人科技企业协会(128CUTE)，麻州香港协会(HKA-MA)，MIT华人科技协会(MIT CAST)，MIT经济与人才论坛(MITETF)，纽英伦中华资讯网络协会(NECINA)，留美华人企业家协会(OCEAN)，纽英伦金融及会计泛亚领袖会(Ascend-NE)和美洲华人生物科学学会(SCBA)共同主办。当天的活动分为下午的社区论坛部分和晚间的新春晚宴和联欢晚会。

**专业论坛畅所欲言**

下午的社区论坛由三场并行的专业论坛和职业资讯组成。三场专业论坛的主题分别为：“美中科技贸易交流”，“商业趋势和创业机会”，及“中美医疗健康”。专业论坛的演讲者均由行业精英、著名人士和政界要员担任。共有300多位专业人士参加了下午的活动。



“美中科技贸易交流”论坛由CABA会长万昭奎博士致开幕词，由陈志宏博士、李劲波博士和王义汉博士分别担任主持人。纽约中领馆科技参赞毛中颖、麻州政府国际贸易及投资处主任吴晓芸、和中国国务院国有资产监督管理委员会研究中心宏观战略研究部部长程伟、辉瑞对外研发创新亚洲部总监丁元华博士、麻州医学院副教授 Dr. Sunny Tam、及中国国家外国专家局韦大玮司长先后就中美科技交流、政府在商务交流中的作用、中国科技体制面临的挑战与发展路径等进行了阐述与评说。



“商业趋势和创业机会”论坛由OCEAN和NECINA主办，旨在探讨当前在中国和美国存在的经济、商业趋势和由此而产生的商业和创业机会。与会者也就创业相关的企业计划、税收等进行了探讨。该论坛由OCEAN会长吴运昭博士致开幕词。由NECINA会长陆德礼博士和CAIPLA创始人张引博士分别担任会议主持。中国国务院国有资产监督管理委员会研究中心宏观战略研究部部长程伟以“海外华侨如何在中国做生意并取得成功”为题生动介绍了华人回国创业要注意的事项。中国社会科学院基金重点项目“中国发展新模式及其战略体系”负责人段培君精辟的概述了中国2010年战略调整与商业机遇。EMC的JAMIE PAPPAS、General Catalyst Partners的Bilal Zuberi博士、长城金融集团创始人杨存辉先生House Center Inc. 总裁王天

齐博士、Nexcelom Bioscience 创始人邱钧博士、KPMG LLP 会计师楼合伙人 Pauline Mak 也分别就新媒体、新能源创业税收等讲述了自己的经验。

“中美医疗健康”论坛由 ACMA 主办。该论坛云集了许多经验丰富的著名华人医生和医学专家并就六大医疗健康问题展开了深入讨论。该论坛分别由张丹茹医生、孔岩平医生、朱正仑教授、任瑞宝教授、胡其宇医生、陈冬芬医生等主持。六大医疗健康问题分别是社区医疗服务、常见病的预防、肝炎和传染病、癌症的防治、心理疾病等。与会者对北美华人社区的常见病的预防和诊治提出了许多值得借鉴的理论和临床经验。

### 社会各界良好祝愿

本次联欢活动备受各界关注，吸引了来自高新技术，生物制药，医疗保险，企业家，法律，金融以及高等教育等不同领域的专业人士近 600 人，其中很多都是各自领域的精英和权威人士。



新春致辞、晚宴和联欢晚会在晚六时三十分开始。由本次活动筹委会共同主席张引博士，中央电视台电影频道《资讯快车》主持人刘晔共同担任晚会主持。大会由 JOSEPH MULLIN 和 JOHNNY IP 代表宣读了美国参议院参议员 John Kerry 和麻州州长 DEVAL PATRICK 分别发来的致贺信，贺信中高度评价了本次活动在引导领域新人融入产业领域的重要意义，以及多元化的专业人士很好的体现了美国式民主。参议员 John Kerry 和州长 PATRICK 表示中国新年表示祝贺。

此次活动筹委会的共同主席王义汉、胡运昭、张引、朱正仑和陆德礼博士对此次活动的成功召开向参与者志愿者和赞助者表示了衷心的感谢和敬意。做主题致辞的知名人士有著名华人数学家，菲尔兹奖（数学界的诺贝尔奖）得主丘成桐教授，麻省理工学院 McGovern Institute 的院长 Robert Desimone 教授，以及哈佛大学肯尼迪政府学院的高级研究员 William Overholt 博士也到场发表了领域演讲和新年贺词。



中国驻纽约总领事馆彭克玉总领事莅临现场并向大家致以新春问候和美好祝福，向到场人士介绍了过去一年中国国内的发展情况，回顾了中国积极参与各种国际合作，充分展现了负责任的大国形象。彭理事还高度评价了广大留美学生和学者，以及海外华人在支持祖国建设和推动中美关系发展中所发挥的重要作用。

### 文化演出精彩纷呈

主题致辞后，伴随著精彩纷呈的中国传统文化演出，浪漫的情人节晚餐开始了。与会者频频举杯，庆祝虎年的到来。文化演出由杨志勇博士和周梅女士共同策划，由沈心焯博士和季晶女士主持。

首先出场的是最具民族文化色彩的舞狮表演《醒狮闹春》，然后由 2008 Jazz Moon 歌唱大赛和 TVB 全球华人新秀分赛区亚军罗阳献上了一曲《天堂》。

在接下来的众多精彩演出中，由中央电视台播音指导，北京语言学会朗诵艺术研究会现任副会长虹云带来的诗朗诵《献给祖国的歌》和《致少女》，令到场来宾对“每逢佳节倍思亲”产生了深深的共鸣，赢得了雷鸣般的掌声。





欢乐喜庆的晚会并没遗忘亟需援助的海地灾民，杨颂女士和谭家玲女士分别为晚会捐助了近期本地文艺演出的入场券，新时代文化社裘崇娅女士也为晚会组织了玫瑰热卖募捐。晚上由车庆林博士，杨钦钊博士等穿插了以赈灾为目的的义拍活动，来宾们踊跃竞投，把节日的祝福承载到无私的援助中。所有款项已陆续交由美国红十字会赈济海地灾民。

接下来的卡拉OK歌舞在 Elaine and Jimmy Lau 的国际标准拉丁舞，和“舞彩人生”国标队的华尔兹舞蹈示范演出后展开。十几位高手大唱爱情歌曲，伴随著熟悉的旋律，来宾们纷纷走下舞池，将晚会的气氛推到了高潮。

来自留美华人企业家协会（OCEAN）会长胡运昭接受了记者的采访，他表示：相比往年，今年的春节嘉年华主办方阵容更为强大，由12个华人协会共同主办。这也是第一次以正式的交流互动方式，到场的嘉宾可以学习、分享，还可以结识新朋友。主持活动音像、舞台、卡拉OK等事宜的朱晓锋博士表示，此次活动让大家共同庆祝新春佳节并增进了不同领域华人专业人士的交流和沟通。

最后，由活动筹委会代表和与会者全体合唱的那首《真心英雄》唱出了所有华夏子女对祖国新年的祝福与期盼，希望祖国亲人和海外华人经历风雨终见彩虹，全力以赴心中的梦。



## 湖北省海外高层次人才招募恳谈会

2010年4月23日，湖北省代表团首次在波士顿地区（Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA）召开海外高层次人才招募恳谈会，湖北省代表向波城专业人士介绍针对海外人才的优惠政策与概况，并进行一对一洽谈。活动吸引了近300名来自马萨诸塞州，罗得岛州，新罕布什尔州，康涅狄格州，纽约州，南卡罗来纳州，伊利诺伊，华盛顿特区，加州等的学生、学者、与专业人士参加。中国驻纽约总领事馆领事姚达也从纽约北上参加。这次活动由美中生物医药协会（CABA），武汉大学校友会和华中理工大学校友会共同承办。



湖北省委常委暨组织部部长潘立钢(左一)、湖北省武汉市组织部部长卢国祥(左二)等人和大波士顿社团代表座谈。CABA会长戴朝阳(后立者)做现场安排。



湖北省委常委暨组织部部长潘立钢(左一)、湖北省武汉市组织部部长卢国祥等人和大波士顿社团代表座谈。



美中生物医药协会董事会主席王义汉、湖北省委常委、省委组织部长、省委人才工作领导小组组长潘立刚先生(中)，美中生物医药协会前会长万昭奎(右)。

CABA 董事会主席王义汉在会议开始介绍该协会服务与活动时，谈到通过在辉瑞制药(Pfizer)工作的华人，促使辉瑞制药在武汉发展投资。CABA 新任会长戴朝阳于午餐时号召大家为青海玉树地震赈灾募捐，募得 686 元，再由 CABA 捐赠 314 元，凑足 1000 元，将由美国红十字会通过中国红十字会转交给灾民。

28 人的代表团由湖北省政府、襄樊市政府官员，和武汉高等院校代表组成，主要成员包括湖北省人才工作领导小组组长潘立刚、武汉市人才工作领导小组组长卢国祥、湖北省外侨办主任马黎、湖北省教育厅副厅长严学军、湖北省科技厅副厅长黄国斌、武汉东湖新技术开发区管委会副主任宋治平、湖北大学副校长邓长青等。恳谈会由华中科技大学党委书记路钢主持。

潘立刚介绍湖北省现况时指出，湖北 2009 年外商投资 46.9 亿美元，人平均 GDP(国内生产总值)逾 6400 美元，实验室数量为全国第三，并有 37 人入选引进海外高层次人才国家「千人计划」。潘立刚代表湖北省政府向海外学人发出了诚挚的邀请。湖北人民目前正在全力打造“惟楚有才，惟楚重才，惟楚用才”的人才集聚区，湖北正张开双臂欢迎各方有识之士，将「用待遇引才，用事业用才，用服务留才」，他欢迎大家明年辛亥革命百年纪念时亲临武汉参观。接着卢国祥推介湖北“3551 人才计划”和“湖北百人人才计划”报告，介绍具有 2 年历史的东湖新技术开发区。东湖为中国第二大科技资源密集的高新区，引才重点包括给予资金支持、开辟绿色通道、培育企业成长、实行奖励，以及给予优惠生活环境。晶丰电子封装材料(EP Materials)副总裁杨钢述说选择在武汉创业的理由。他在美做研发多年后，把握住中国给予海外人才的优惠方案回国创业。他认为，武汉高等学校集中，容易招揽人才，东湖高新区充满活力，而且湖北省地理位置居中。此外，低廉消费也有助于降低成本。武汉政府并协助他入选「千人计划」。杨钢的半导体材料公司也同时在美注册，正符合潘立



湖北海外高层次人才招募座谈会现场。

刚所说，海归不是放弃美国一切，而是获得更多机会。个人与团体在交流互动间制造出无数机会。宋治平表示，东湖高新区二年来的海外招才活动，已吸引 300 人创业。

在自由提问时，一些听众向代表团提出了关于回国创业的具体问题，譬如询问持中国护照或美国护照是否会影响回中国发展，项目资金分配机制，需要人才的层次，由于时间关系，许多听众没有得到详细的回答，但是在自由提问后，代表团特意在会场设置“人才服务受理处”，听众可以直接向人才需求单位去登记，咨询，洽谈并签订相关合约。

报道：美中生物医药协会常务理事 刘汉兰博士  
摄影：星岛日报记者 周菊子

## 中国苏通科技产业园代表团访波士顿进行推介活动

中国苏通科技产业园代表团一行四人于五月十四日抵达波士顿，在波士顿 Double tree 酒店为跨苏州、南通两市的该科技开发项目举行推介活动，此项推介活动由美中生物医药协会召集和主持，共吸引了近五十名新英格兰地区的学者，科技人士和企业家参加。

该团团长、苏通科技产业园副主任李玲女士表示，苏通科技产业园是江苏省沿海开发和跨江联动开发的重点项目，位于苏通大桥

北翼，是江苏沿江、沿海发展的交汇点，地处沪、苏、通「小三角」的中心点，距上海、苏州一小时以内车程，是南通接轨上海、融入苏南的桥头堡。

李玲表示，基于中新双方专家建设国际化城市的经验，苏通科技园将建成为一个新兴的高科技，人文生态型的宜居地，规划人口三十万。园区重点鼓励节能环保，新能源，生物科技，机电设备制造，电子信息，新材料和现代服务产业。园区具有国家级开发区的审批权限。将对符合条件的海外投资和海归人才将给与税收和各方面的政策优惠。



苏通科技园波士顿推介会于五月十四日在 Doubletree 酒店举行

会后，与会代表就相互感兴趣的话题进行了提问和交流。部分与会者还与苏通园区代表团就具体项目进行了一对一的洽谈。

此次活动取得了圆满成功。苏通产业园区非常感谢美中生物医药协会对此次推介会的大力支持和帮助，也希望和美中生物医药协会加强合作，帮助宣传和推广苏通产业园，为苏通产业园积极推荐人才和项目。对苏通园区感兴趣的人士可以浏览园区网站 [www.stpac.gov.cn](http://www.stpac.gov.cn)，或洽 AJLW 咨询公司 John Wang 博士 (sfjohnwang@yahoo.com)

## “药物研发在中国”学术研讨会

美国化学会东北地区分会（NEASACS）和美中生物医药协会（CABA）合作，五月 22 日在 Woburn 市 Holiday Inn 举办「中国药物研发：现状、机遇、国际合作及挑战」学术研讨会，超过 150 名学术界与生物制药界人士到会，会议内容分三个主题：中国药物研发现状，国际合作带动中国药物研发，以及药物研发在中国的机会及挑战；分别由王渊，吕志坚，和项仪宾主持。

美国化学会东北地区药物化学分会主席邵黎明和美中生物医药协会会长戴朝阳指出，目前中国的药物外包业风靡全球，所以过去举办的制药讲座多以医药研发外包公司（Contract Research Organization, 简称 CRO）为主。但近来因为中国政府、学界与民间企业投入大量资源到制药研发中，他们相信未来中国新药研发市场大有可为。除了当地医药界人士外，主办单位特地从中国邀请了中国科学院上海药物研究所研究员沈竟康、中国药科大学新药研究中心主任孙宏斌、中国 KBP 生物制药公司负责人宋运涛、苏州圣诺生物医药技术有限公司(Suzhou Sinnaomics Biopharmaceuticals) 副董事长杨宏钧、Novartis 诊断和疫苗部亚洲地区开发主管廖想，以及先声药业（Simcere Pharmaceutical Group）首席科学官王鹏等人。

沈竟康研究员介绍了中国药物研究的发展。他表示，在 90 年代前，中国很少进行新药研究与开发，仅有学术单位针对新药进行研究。不过由于中国政府决心推动生物制药业的发展，因此从 1985 年 实施专利法，1993 年立法针对化合物进行专利保护，随后的新药立法，有助药物研究的发展。从 90 年代至今，药物研发平台逐渐建立、中国政府亦给予大笔经费资助研究。沈竟康强调，其中最特别的就是学术单位与生物制药业界的合作，同时以市场作为新药研发导向。将来中国发展制药市场上的走向是因应中国人口的量大及老化事实，追随 GDP 成长走势，配合医保体系，社会城市化，并迎合还未满足的药物需求，以期最终能够「在中国制造，在中国研发」。沈竟康在会中介绍了中国上海药业公司现在是中国排名第二的制药公司，有 2900 种产品，营业额达 348 亿元人民币。共登记了 277 个新药，享有 248 项专利。沈竟康还在会中介绍了中国两家制药公司：恒瑞和保全。

Tufts 大学药物发展中心副教授 Christopher-Paul Milne 当天以「世界研发趋势：中国制药业的全球观点」为题发表讲谈。他指出，宏观来看，数目就能说出个故事，到处都是改变，机会满天飞。首先是生物制药比传统制药要节省时间、经费，开始更受重



邵黎明(左三)、戴朝阳(右二)以及讲座主持王渊(右一)等人和讲者孙宏斌(左一)等人合影。



CABA 会长戴朝阳(后立者)主持专家现场小组讨论。

视，但药物的产制与否，有一半是出于商业决定。全球研发投资有向亚洲及东欧中部国家流动的趋势。其中一项重要因素是临床研究费用。他指出，目前药物研发界面对的挑战是工艺、产品及模式都需改变。对中国来说，在研发成长被低估之际，市场成长可能过热了，但中国有丰富收获的机会。

孙宏斌以「新药研发：从旧药开始」为题，引述诺贝尔奖得主布莱克（James Black）所说：「成果最丰硕的新药研发基础就是从现有的药物开始」，他认为，制药界可广为开发现存药物的新用途。孙宏斌举例，「Raloxifene」原本用来治疗骨质疏松症，新用途则是治疗乳腺癌；「Methazolamide」原本用来治疗青光眼，新用途是治疗糖尿病；「Gossypol」原本用来治疗子宫内膜异位症，新用途是治疗前列腺癌等。孙宏斌表示，将多种现有药物结

合后用以治疗疾病的方法，也广泛应用于医疗界，包括：爱滋病鸡尾酒疗法、多种抗癌药物的结合。最引人注目的莫过于将阿司匹灵加上 Dipyridamole，成为预防二度暂时性脑血管缺血或缺血性脑中风的药物。孙宏斌认为，新药的研发，不可忽视医学临床实证与流行病学研究的证据，同时，医师与药剂师、制药界也应建立更好的互动。

哈佛大学医学院天然产物研究科学主任 Bruce Littlefield 讲谈「在哈佛医学院建造一个有质量控制的，有来源证据的传统中国天然药物库」开发新药国际合作时指出，治病的药物，有 50% 来自天然药物，治疗癌症的更高达 70%，可见了解大自然中的可用动植物，有多重要，但可惜的是，支持该一计划的经费来源，最近已中止。

宋运涛讲述了怎样建立 KBP Bioscience，一个中国新药研发公司的经历，他特别强调通过选择临床证明过的生物靶向来降低新药研发风险，另外医药研发外包公司也为中国新药研发奠定了基础和加快了速度。杨宏均讲谈了苏州圣诺生物医药技术有限公司在苏州生物园(BioBay)内研发 RNAi 药物治疗传染性流感，皮肤

外伤恢复等疾病。先 声药业首席科学官王鹏主要讲述该公司和美国生物制药企业 Epitomics 公司研发项目 Sim-BD0801, humanized 抗 VEGF 的兔蛋白，针对中国市场研发的 Sim-BD0801 成为世界首款针对癌症的 Rabbit-derived 抗体药，这种首上市药物和创新药开发模式为国内医药企业站在全球顶级医药研发领域制高点树立了极佳的榜样。

吕志坚从辉瑞公司的角度谈和其他公司合作来达到新药研发与生产上的创新与成功。Dr. Luciene Ronco from Astra Zeneca 讲述了 Astra Zeneca 公司在中国新建的研发中心概况，该中心侧重癌症临床研究。

在美中生物医药协会会长的戴朝阳的主持下，并进行小组讨论。当天其他的演讲人还包括 Milstein, Zhang & Wu 律师事务楼的张引律师和 Finnegan 的 McGurk 律师讲谈如何在中国取得知识产权的保障。

报道：美中生物医药协会常务理事 刘汉兰博士

摄影：星岛日报记者 菊子

## 华创会生物医药高峰论坛 2010 Wuhan Hua-Chuang-Hui Bioforum

2010 年 9 月 15 - 17 日  
中国湖北省武汉市



## 美中生物医药协会将参加第十届 华创会并主持国际生物医药论坛

美中生物医药协会将连续组队参加在湖北武汉国际会展中心举行的 2010 华侨华人创业发展洽谈会。本届“华创会”由国务院侨务办公室、湖北省人民政府暨武汉市人民政府共同主办，湖北省侨办、湖北省科技厅、武汉市侨办、武汉东湖新技术开发区管委会承办。这将是美中生物医药协会第三次组队参加华创会。

由协会董事会主席王义汉博士带队，美中生物医药协会代表团此行将主持 2010 国际生物医药论坛。去年，该论坛共吸引海内外的生物医药界人士约 400 人参加，CABA 和美中生物医药联盟共组织了来自美国、加拿大等国家 10 名优秀海外生物医药行业代表演讲。另外，在湖北方面和 CABA 的共同努力下，首届国际医疗器械论坛也将在华创会上也将首次与参会者见面，该论坛将讨论医疗器械和诊断行业的最新进展，及相关技术的革新与前瞻。应国务院侨务办公室科技司的邀请，王义汉博士还将在华创会期间代表美中生物医药协会出席第四届海外华侨华人专业协会会长联席会并演讲。

美中生物医药协会代表团此行还将访问北京，天津，石家庄，无锡等地的生物医药产业园区和部分企业。

**CABA Global Express****BioMedical News Round-Up**

Compiled by Jingye Zhou, Ph.D.

**CHARLES RIVER, WUXI CALL OFF \$1.6B DEAL**

Shareholder opposition has forced Charles River to call off its \$1.6 billion plan to purchase China's WuXi PharmaTech (药明康德). Despite CEO James Foster's assurances that the deal would bring up to \$100 million in potential operational savings, several investors were never able to overcome their concerns that the deal wasn't in the company's best interests. Charles River has been expanding its Chinese operations for the past several years and had hoped to increase the size of its footprint in China with the WuXi deal. Investors Jana Partners, Relational Investors and Neuberger Berman were among the firms concerned that Charles River was overpaying for the Chinese CRO, and that the company would face significant challenges integrating the two businesses. The termination agreement provides for Charles River to pay WuXi a \$30 million

**NOVARTIS TO EXPAND ITS CHINA OPERATION**

Novartis AG will expand its research and sales force in China with its own employees. The company has plans to invest \$1 billion for a six building research campus in Shanghai that could ultimately employ 500 scientists. As pharmaceutical makers struggle with slow-growing western markets, tough regulators, falling prices and a lack of blockbuster drugs, China is emerging as their newest center for research, partly at the urging of local regulators. Often working in collaboration with local companies and universities to outsource

basic research, global drug makers hope a combination of cheaper talent and fresh discoveries in the country might buoy their operations.

**PFIZER LINKS UP FOR TB R&D IN CHINA**

Pfizer will work with MicuRx Pharmaceuticals (盟科医药) and Cumencor Pharmaceuticals to discover treatments for multi-drug-resistant tuberculosis. Under the deal, Pfizer will make an upfront payment and provide funding for discovery and preclinical development of novel antibiotics. All research will be conducted at Shanghai's Zhangjiang Hi-Tech Park, where MicuRx operates labs. Based in Hayward, Calif., MicuRx was formed by two scientists from Vicuron Pharmaceuticals, which Pfizer acquired in 2005. Cumencor is a China-based biotech firm applying MicuRx's anti-infective discovery techniques.

**COLD SPRING HARBOR SETS UP NEW BRANCH IN SUZHOU**

The Cold Spring Harbor Laboratory launched an Asian campus on April 6 in Suzhou, China, marking the establishment of CSHL's only subsidiary outside the U.S. Nearly 320 scientists attended the inaugural event, which was followed by a five-day "James Watson Symposium on Cancer." The symposium drew a diverse group of speakers mainly from Asia, Europe, and North America.

**CHINA, US OPEN DISEASE STUDY CENTER IN SHANGHAI**

American and Shanghai health authorities opened an epidemiology center in the

Chinese city Tuesday to train experts in sleuthing out ways to prevent chronic and epidemic diseases. The U.S. Centers for Disease Control and Prevention is helping with training and technical assistance at the center that will be "driven by what are the major public health issues in this country," said CDC deputy director Stephen B. Thacker.

**PFIZER SELLS CHINA SWINE VACCINE UNIT TO HARBIN PHARMACEUTICALS**

To win approval in China, Pfizer has agreed to sell an animal vaccine for a reported \$50 million to Harbin Pharmaceuticals, which is mostly owned by a provincial government and Citic Capital, a state-affiliated Chinese investment group.

If not for the sale, Chinese antitrust officials argued that Pfizer would now control half of the domestic market for mycoplasma hyopneumoniae vaccines, which are used to inoculate pigs. The Financial Times points out, adding that experts believe the sale is likely to be the first of many more transfers of intellectual property to Chinese groups arising from antitrust rulings. The vaccine is made in Nebraska and Pfizer retains the IP rights to RespiSure outside of the mainland and now will only sell Wyeth's MH vaccine in China, which has a 12 per cent market share. As part of the agreement, Pfizer has to provide Harbin with technical assistance and training for up to three years to help it learn how to produce the vaccine.

**CABA Career Center****Selected Pharmaceutical, Biotech & CRO Job Opportunities***Compiled By Tony Yuan*

Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization of Novartis. With approximately 5 000 scientists and physicians around the world, our research is focused on discovering innovative new drugs that will change the practice of medicine. We have an open and entrepreneurial culture, encouraging collaboration to make effective therapies. Apply online: [www.novartis.com/careers/](http://www.novartis.com/careers/)

**Selected Openings in Cambridge, MA**

ADME/DMPK Investigator  
Associate Scientist - Molecular Diagnostics  
Biostatistician, Gene Expression  
Epigenetics Research Investigator  
Enzymology/Biochemistry Research Associate  
Epigenetics Research Scientist  
Global Head Scientific Support  
Translational Sciences  
Group Leader, Medicinal Chemistry  
Hits Discovery Group Leader  
In vivo and Molecular Biology  
Research Associate  
Medicinal Chemistry  
Associates/Scientists  
Molecular Histologist  
Molecular Pathologist, Investigative  
Toxicology  
Oncology Pharmacologist BS/MS  
Scientist  
Pharmacogenetic Analyst  
PhD Medicinal/Synthetic Organic  
Chemist  
PhD Scientist- Oncology Biology  
PhD Scientist-In Vivo Physiology -  
Muscle Disease  
PhD Scientist: Antibody Therapeutics

PhD Scientist: Ophthalmology Gene  
Therapy  
Project Lead Translational Sciences  
Protein Biochemistry Research  
Associate  
Scientist I - Molecular Toxicology  
siRNA Drug Delivery Chemist  
Small Molecule NMR Scientist  
Target Validation Investigator



Pfizer offers a wide range of pharmaceutical career opportunities from research and development and business technology to marketing and pharmaceutical sales.

Pfizer provides reasonable accommodation in job application procedures for qualified individuals with disabilities and disabled veterans. If you have a disability that inhibits your ability to apply for a position through our online application process, you may use the alternative methods described below to contact us about your interest in Pfizer. Contact Pfizer: [globalrecruitinginbox@pfizer.com](mailto:globalrecruitinginbox@pfizer.com)

**Selected Openings in Massachusetts**

Computational Biologist  
Biomeasure/Biomarker Scientist R4-R6  
Director / Sr. Director (MD/PhD)  
Orphan and Genetic Diseases Research  
Unit  
Group Leader, Novel Immune  
Receptor  
Senior Scientist (Enteroendocrine Cell  
Biology)  
Assay Development and Biochemical  
Characterization R3/4  
In Vivo Study Scientist (R2-R3)

Director/Senior Director, Rare Diseases  
Research Unit  
Senior Scientist / Protein Modeler,  
Biotherapeutic Engineering and  
Production  
Associate Scientist/Sr. Associate -  
Biotherapeutics Research  
Associate Director/Director, Clinical  
Sr. Director -Translational  
Immunology/ ClinRes MD.PhD.-  
Inflammation & Immunology  
Oligonucleotide Chemist  
ADME Scientist Position (R5-R7)  
Manager, Global CMC, Biologics  
PhD Research Scientist - Senior  
Scientist, Inflammation and  
Immunology  
Separations Scientist (Scientist/ Senior  
Scientist)



Sundia MediTech is a leading integrated pharmaceutical contract research organization (CRO) based in Shanghai, China. With our technical expertise and excellent research facilities, we offer broad and integrated chemical services, medicinal chemistry, biological services, new technology platforms and pharmaceutical development services.

At Sundia, every employee is critical to our success. For talented and creative people like you, future career paths can be rich and varied. Sundia offers you endless possibilities to use all of your professional and interpersonal skills to help us create the future together. If you want to be part of Sundia, please prepare a cover letter indicating the position you are applying for and the matching skills, along with a resume including references and publications. Please email the

materials to [hr@sundia.com](mailto:hr@sundia.com). Alternatively you can search for a job and submit your resume online. Sundia offers competitive compensation and a benefits package, as well as an exciting atmosphere conducive to career growth.

### Selected Openings

Project Manager of Formulation  
Group Leader of DMPK  
Project Manager of DMPK  
Scientist in Pre-formulation  
Scientist in Formulation  
Chemistry Scientist  
Bioinformatics Researcher  
Analytical associate scientist



WuXi AppTec, a NYSE listed public company, offers global pharmaceutical/bio- pharmaceutical companies diverse outsourcing services in combinatorial, medicinal, synthetic chemistry and manufacturing of APIs and finished drug products for preclinical and clinical trials. Our clients include over 80 leading global pharmaceutical and biotech companies in the U.S., Europe and Japan.

WuXi AppTec welcomes overseas chemists and formulators join us. We offer you a highly competitive compensation and full benefits package along with an exciting world-class work environment. For more information, please visit our website: <http://www.wuxiapptec.com/>. For prompt consideration, please send your CV to: [hr@wuxiapptec.com](mailto:hr@wuxiapptec.com).

### Shanghai Opportunities


Vice President of Medicinal Chemistry  
Executive Director /Senior Director /Director of Medicinal Chemistry  
Project Team Leader of Medicinal Chemistry  
Principal Scientist/Senior Scientist of Medicinal Chemistry  
Senior Director /Director /Associate Director of Enzymology

Executive Director/ Senior Director/  
Director of Formulation Development

Senior Director/ Director of Pre-  
formulation Development  
Executive Director/ Senior Director/  
Director of Process R&D  
Senior Director/ Director of Analytical  
R&D  
Senior Director /Director /Associate  
Director of Receptor Pharmacology  
Research Fellow, In Vitro Biology  
Principal Scientist of Stem Cell  
Research  
Senior Scientist of Stem Cell Research  
Scientist of Stem Cell Research  
Executive Director/Senior  
Director/Director of DMPK  
Senior Director/Director of  
Pharmacology  
Senior Director/ Director of Analytical  
R&D/QC  
Computational Chemists

### Suzhou Opportunities

Study Director of Toxicology  
Veterinarian Ophthalmologist  
Attending Veterinarian  
Clinical Pathologist  
  
Pathologist  
Biologist III/Biocompatibility  
Biologist III/Trainer



People are our most valuable asset and the source of innovation at SYN |thesis. SYN |thesis's goal of delivering high

quality service in a timely manner is predicated upon attracting excellent scientists and managers, and providing a friendly, energetic, dynamic and nurturing working environment in which they can grow and thrive. SYN |thesis is constantly seeking people with high ethical standards, a passion for quality, and a dedication to science.

### Current Opportunities:

- Vice President in Chemistry, Shanghai, China
- Senior/Director in Medicinal Chemistry, Shanghai, China.

If you are highly talented and motivated individuals and want to become part of part of SYN |thesis's growing family, please submit your resume to [hr@synmedchem.com](mailto:hr@synmedchem.com) or [xian.bu@synmedchem.com](mailto:xian.bu@synmedchem.com)

## CABA Leadership Team Update

# 2010-2011 CABA Executive Committee and Key Team

### President

Chaoyang Dai, Ph. D.  
Principal Scientist, Merck Research  
Laboratories, Cambridge, MA

### Vice Presidents

Zhiyong Yang, Ph. D.  
Principal Research Scientist, Pfizer  
Inc., Cambridge, MA

Qinglin Che, Ph. D.  
Research Scientist, Synta  
Pharmaceuticals Corp., Lexington,  
MA

Zhihong Chen, Ph. D.  
Sr. Research Investigator, Eisai  
Research Institute, Andover, MA

Sue Ma, M. D.  
Scientist II, Novartis Institute of  
BioMedical Research, Cambridge,  
MA

### Executive Committee Members

Kevin Fang, Ph. D.  
Director of Chemistry, Sepracor Inc.,  
Marlborough, MA

Fred Hu, Ph. D.  
Principal Research Scientist, Pfizer  
Inc., Cambridge, MA

Jia Huang, Ph. D.  
Scientist, Allergan Inc., Cambridge,  
MA

Jinbo Lee, Ph. D.  
President, Sage International Inc.,  
Cambridge, MA

Shengfang Jin, Ph. D.  
Director/Cell Biology, Agios  
Pharmaceuticals, Inc., Cambridge,  
MA

Fushuang Liu  
Vice President, Wuxi Howfond  
Biopharma Co., Ltd., Wuxi, China

Hanlan Liu, Ph. D./MBA  
Director/DMPK, Genzyme  
Corporation, Framingham, MA

Haihong Ni, Ph. D.  
Director of Computational Science,  
Chemizon, Beijing, China

Shallwei Sun  
President, Callisyn Pharmaceuticals,  
Inc, Boston, MA

Ze Tian, Ph. D.  
Investigator, Children's Hospital  
Boston/Harvard Medical School,  
Boston, MA

Yongzhong Wang, Ph. D.  
Staff Scientist, Genzyme  
Biosurgery/MTS, Cambridge, MA

Zhigang Wang, Ph. D.  
Sr. Principal Scientist, Pfizer  
Research Technology Center,  
Cambridge, MA

Roger Xie, Ph. D.  
Co-founder, EVP, Head of Global  
Development, China PharmaHub  
Corp., Cambridge, MA

Herong Yang, Ph. D.  
Chief Architect, Open Channel  
Solutions, Boston, MA

Yongwen(Tony) Yuan  
Cheminformatics Specialist, Novartis  
Institute of BioMedical Research,  
Cambridge, MA

Philip Zhang, Ph. D.  
Co-founder and Co-Managing  
Principal, Milstein Zhang & Wu LLC,  
Newton, MA

Wei Zhang, Ph. D.  
Staff Scientist, Siemens Healthcare  
Diagnostics, Norwood, MA

Weiyi(Wendy) Zhang, Ph. D.  
President, Boston Lincoln  
International, Lincoln, MA

Liping Zhou, Ph. D.  
Investigator, Novartis Institute of  
BioMedical Research, Cambridge,  
MA

Zhendong Zhu, Ph. D.  
Principal Scientist, Avila  
Therapeutics, Inc., Waltham, MA

### Chairman, Board of Directors

Yihan Wang, Ph. D.; Associate  
Director/Chemistry, ARIAD  
Pharmaceuticals, Inc., Cambridge,  
MA

### Board of Directors

Jun Han, Ph. D.; *Founding President*  
Global R&D Project Manager, Teva  
Pharmaceuticals, Inc., Pomona, NY

Shiwen Lin, Ph. D.  
Associate Director, Antigenics, Inc.  
Lexington, MA

Lixin Shen, Ph. D.  
President and CEO, Wuxi Howfond  
Biopharma Co., Ltd., Wuxi, Jiangsu,  
China

Zhao-Kui Wan, Ph. D.; *Immediate  
Past-President*  
Principal Research Scientist, Pfizer  
Inc., Cambridge, MA

Erxi Wu, Ph. D.  
Investigator, Harvard-MIT HST  
Division, Boston, MA

Junjun Wu, Ph. D.; *Past President*  
Principal Research Scientist, Pfizer  
Inc., Cambridge, MA

### CABA Advisors

Tomi Sawyer, Ph. D.  
Chief Scientific Officer and Senior  
Vice-President, Aileron Therapeutics,  
Cambridge, MA

Yibin Xiang, Ph. D.  
Senior Director/Medicinal Chemistry,  
Genzyme Corporation, Cambridge,  
MA

Gangfeng Xu, Ph. D.  
Sr. Director/Head of Asia & Pacific  
Business Development, Pfizer Inc.

Howard Yuwen, Ph. D.  
Sr. Director, Shire Pharmaceuticals,  
Cambridge, MA

Chen Li, Ph. D.  
Head of Research and Chief  
Scientific Officer, Roche R&D  
Center(China) Ltd.

Steve Yang, Ph. D.  
Vice President and Head of Pfizer  
Asia R&D (Shanghai), China

Tim Clackson, Ph. D.  
Sr. VP and Chief Scientific Officer,  
Ariad Pharmaceuticals Inc.,  
Cambridge, MA

Youssef Bennani, Ph. D.  
Vice President/Discovery Chemistry,  
Vertex Pharmaceuticals Inc.,  
Cambridge, MA

Dawei Ma, Ph. D.  
Professor, Shanghai Institute of  
Organic Chemistry, Shanghai, China

Roger Tung, Ph. D.  
CEO and President, Concert  
Pharmaceuticals, Lexington, MA

Steve Projan, Ph. D.  
Vice President, Global Head of  
Infectious Diseases, Novartis Institute  
of BioMedical Research, Cambridge,  
MA

John Piwinski, Ph. D.  
Group VP and Site Head, Merck  
Research Laboratories, Cambridge,  
MA

Tarek Mansour, Ph. D.  
EVP, Xenon Pharmaceuticals Inc.,  
Vancouver, Canada

Liming Shao, Ph. D.  
Senior Director/Medicinal Chemistry,  
Sepracor Inc., Marlborough, MA

Pierre Dodion, M. D., MBA  
Sr. VP and Chief Medical Officer,  
Ariad Pharmaceuticals Inc.,  
Cambridge, MA

Yuanli Liu, Ph. D.  
Director of China Initiative, Sr.  
Lecturer on International Health,  
Harvard School of Public Health

Shi Li, Ph. D.  
Senior Director/Technology  
Development, Genzyme Corporation,  
Framingham, MA

Tse Ping  
Chairman, Sino Biopharmaceutical  
Ltd., Beijing, China

Suvit Thaisrivongs, Ph. D.  
Vice President, Pfizer, Inc.,  
Cambridge. MAARIAD  
Pharmaceuticals, Cambridge, MA

### CABA Legal Council

Fred Gilman  
Attorney at Law, Lynch, DeSimone  
& Nysten, LLP, Boston, MA

**CABA Sponsors Update**

**2010-2011 CABA Annual Sponsors and Event Sponsors**

**Annual Sponsors**



**Event Sponsors**



专业研讨 学术交流 项目对接 招商引资



(位于武汉长江蛇山之颠的天下江山第一楼---武汉黄鹤楼)

华创会生物医药高峰论坛

## 2010 Wuhan Hua-Chuang-Hui Bioforum

2010年9月15 - 17日

中国湖北省武汉市

国务院侨办, 湖北省药监局(Hubei-SFDA), 湖北省暨武汉市人民政府, 武汉国家生物产业基地  
美中生物医药协会(CABA, Chinese-American BioMedical Association)

**Deadline:** Please submit your application by Aug. 15, 2010

**Website:** [www.cabaweb.org](http://www.cabaweb.org), [www.hch.org.cn](http://www.hch.org.cn) and [www.biola.gov.cn](http://www.biola.gov.cn)

**Contact:** Drs.Zhihong Chen ([zhihongchen06@yahoo.com](mailto:zhihongchen06@yahoo.com)), Zhaokui Wan ([zhaokuizkwan@yahoo.com](mailto:zhaokuizkwan@yahoo.com)),

**Who can apply:** Scientists/Entrepreneurs/Companies in life science field (Bio/Pharma, Medical Device and Diagnostics, etc) who are seeking opportunities in Central China.

**Visit Other Cities:** Beijing, Tianjin, Shi Jia Zhuang (石家庄), Suzhou, Wuxi, etc

武汉欢迎你!  
美国CABA团队与你同行

**Howfond****In China, Custom Drug Discovery: Low Cost, High Quality!**

**Wuxi Howfond Biopharma Co., Ltd.** (无锡好芳德药业有限公司) located in Wuxi, China, is a research-driven and customer-focused company. With 150,000 sq ft modern R&D and manufacturing facilities, Wuxi Howfond offers global pharmaceutical and biotech companies a broad portfolio of custom services for drug discovery, development and production.

**Services On Chemistry**

FTE Contract Research: Discovery chemistry to lead optimization / hit and lead follow-up, and focused library synthesis / process development  
 Custom Synthesis: Building blocks / library templates / libraries / intermediates / literature and commercial reference compounds  
 Scale-up Synthesis: Intermediates to APIs / milligrams to tons quantity

**Services On Pharmacokinetics/Pharmacology**

ADMET Studies  
 Protocol Design  
 Formulation Development  
 In-life Study  
 Sample And Data Analysis  
 Report Preparation  
 Animal Models

**Synthetic Experiences**

Heterocyclic Compounds  
 Pyrimidines, Pyrazoles, Pyrroles,  
 Pyridines, Oxazoles, Quinolines,  
 Indoles, Triazole and Tetrazoles  
 Arylboronic Acids  
 Unnatural Amino Acids

**Expertise On Chiral Synthesis**

Asymmetrical Catalysis  
 Resolution of Enantiomers  
 Total Synthesis of Natural Products

South Bldg, 1608 Huishan Blvd, Huishan District, Wuxi, China 214174 Tel: +86-510-8359-1618 x 8011 Fax: +86-510-8359-1616  
 <sales@howfond.cn> <www.howfond.com>

**Sundia****Your Partner for Drug Discovery and Development**

- **Top CRO in China**
- **Integrated R&D Services for Drug Discovery and Pharmaceutical Development**
- **Deloitte Technology Fast Top 50 Award in China, Deloitte Asia Pacific 500**
- **Venture Top 50 Award by Zero2IPO**

Reach thousands of professionals, executives and scientific researchers in biomedical industries throughout the world!

Advertise in CABA CONNECT

Contact our advertisement editor at [cabacconnect@gmail.com](mailto:cabacconnect@gmail.com)

Deadlines:

November 31, 2010 for winter '10 issue.

CABA members, send your comments, suggestions and thoughts to us; Contribute to "Member Spotlights" column by sending us a brief summary of your recent achievements on academics or/and careers.

Volunteer needed for news reporting, editing and photography. Great opportunity for networking! Contact us if you are interested. Email: [cabacconnect@gmail.com](mailto:cabacconnect@gmail.com)

## Upcoming Events

### 10<sup>th</sup> Wuhan Hua-Chuang-Hui (华创会)

September 15th ~17th, 2010

Location: 武汉香格里拉大酒店, 武汉科技会展中心

Website: [www.hch.org.cn](http://www.hch.org.cn)

### 2010 Regulatory Training Graduation Ceremony

Organized by CABA Education Center

Saturday, October 2nd, 2010

Location: MIT

Website: [www.cabaweb.org](http://www.cabaweb.org)

### 2010 CABA Technology, Investment & Entrepreneurship Symposium In Association with "Hunan Night" Reception

Co-organized by CABA, MOITI & Hunan Provincial Government

Saturday, November 13th, 2010

Time: 12:00 PM - 9:30 PM

Location: Doubletree Guest Suites Boston, 400 Solders Field Rd, Boston, MA

Website: [www.cabaweb.org](http://www.cabaweb.org)

### 2010 CABA Medical Devices and Diagnostics Symposium

Organized by CABA & NECINA (co-organizers: CAIPLA, OCEAN, ACMA)

Saturday, December 4th, 2010

Location: IBM Innovation Center, 404 Wyman St, North Entrance, Waltham, MA

Website: [www.cabaweb.org](http://www.cabaweb.org)



Chinese-American Biomedical Association

P. O. Box 600241

Newtonville, MA 02460 USA

[www.cabaweb.org](http://www.cabaweb.org)

Non-profit Org.  
US postage paid  
Newton, MA 02460